Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BLOCK ASPIRIN/SALICYLAMIDE COMBO RELIEVES PAIN 17 MINUTES "SOONER"

This article was originally published in The Tan Sheet

Executive Summary

BLOCK ASPIRIN/SALICYLAMIDE COMBO RELIEVES PAIN 17 MINUTES "SOONER" than aspirin alone, Block Drug reported in a study submitted to FDA to support monograph status of 195 mg salicylamide as an analgesic adjuvant to 650 mg aspirin. Conducted by Stephen Cooper, PhD, et al., the double blind, randomized, parallel group study compared efficacy profiles for four preparations -- placebo, 650 mg aspirin, 650 mg aspirin with 195 mg salicylamide, and 1,300 mg aspirin -- and found that onset of pain relief "occurred 17 minutes sooner" in the aspirin/salicylamide group than in the 650 mg aspirin group. Block Drug markets BC Powder analgesic product which contains the aspirin/salicylamide combination.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083151

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel